Kobiolab

Venture Capital
PORTFOLIO

Industry : Therapeutics & Food (Microbiome)

Investment Year : 2014
Investment Type : Early Stage

Kobiolab is possessing more than 5,000 microbiome strains originated from Korean Human race. DB’s of microbiome, pre-clinical tests, and so on are the most competitive point in the industry.

Kobiolab is the leading Microbiome company in South Korea. CEO, Dr. Ko had won Ph.D in Havard University in Microbiome, became a professor in Seoul National Univ. and established Kobiolab in 2014.

Kobiolab is possessing more than 5,000 microbiome strains originated from Korean Human race. DB’s of microbiome, pre-clinical tests, and so on are the most competitive point in the industry.

The company is targeting the microbiome therapeutics, However the company is also focusing on the early business and cash from microbiome healthy food, which is supposed to launch in 3Q of 2018.